Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Chemotherapy in Neoadjuvant TNBC
NCT02883062Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Started Aug 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02883062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883062.